Eurofins clinical diagnostics laboratories offer a broad portfolio of tests focused on cancer predisposition and cancer risk monitoring. These novel tests make early cancer diagnosis for possible high-risk individuals.

Serum biomarkers have been used for many years to support cancer diagnosis. The alteration of any serum markers indicates an organ malfunction which could be caused by cancer.  With this information as a starting point, a clinician will look for a confirmatory diagnosis by other means. If cancer diagnosis is confirmed, tumour characterisation through biopsy will be the next step. Genetic testing offers molecular tumour profiling which provides a full picture of the clinical situation.

Advances in genetics and proteomics allow for personalised treatment of patients that translates to lower risk of recurrence and better prognosis. Eurofins clinical diagnostics laboratories are committed to contributing to the advancement of personalised medicine and have invested heavily in new genetic tests to offer the best possible support to clinicians so that they may provide the very best care to patients. 

Molecular characterisation of tumours or tumour profiling is used for diagnosis and treatment definition as well as to monitor patient prognosis. Eurofins clinical diagnostics laboratories offer DNA- and RNA-based tests as well as proteomics which, when combined with a patient’s clinical history, can provide insights on cancer staging and malignancy level.